Impact of a sustained virological response on the long-term outcome of hepatitis C

Liver International

Volumn 31, Issue SUPPL. 1, 2011, Pages 18-22

  Alberti, Alfredo ^a  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Cirrhosis progression; Decompensation; Fibrosis; HCC; Modelling; Natural history; Outcomes; Remission

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PORTAL HYPERTENSION; REMISSION; RISK REDUCTION; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; VIRAL CLEARANCE;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; TREATMENT OUTCOME;

EID: 78650823246     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02378.x     Document Type: Article

References (23)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. American association for the study of liver diseases diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
2. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 2009; 49: 665-75.
3. Bartolomé J, López-Alcorocho JM, Castillo I, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007; 81: 7710-5.
4. Radkowski M, Horban A, Gallegos-Orozco JF, et al. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. J Infect Dis 2005; 191: 1730-3.
5. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
6. Chavalitdhamrong D, Tanwandee T. Long term out-comes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol 2006; 12: 5532-5.
7. Marcellin P, Boyer N, Gervais A, et al. Long-tem histological improvement and loss of detectable intrahepatic HC RNA in patients with chronic hepatitis C and sustained response to interferon alfa therapy. Ann Int Med 1997; 127: 875-81.
8. Zeuzem S, Diago M, PEGASYS Study NR16071 Investigator Group et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
9. Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005; 42: 266-74.
10. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
11. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
12. Toccaceli F, laghi V, Capurso L, et al. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003; 10: 126-33.
13. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504-8.
14. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-9.
15. George SL, Bacon BR, Brunt EM, et al. Clinical, virological, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follw-up of 150 patients. Heatology 2009; 49: 729-38.
16. Poynard T, Ngo Y, Munteanu M, et al. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther 2010; 15: 617-31.
17. Wang JH, Changchien CS, Hung CH, et al. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: longitudinal study using FibroScan. J Gastroenterol Hepatol 2010; 25: 964-9.
18. Arora S, O'Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006; 21: 406-12.
19. Omland LH, Krarup H, DANVIR Cohort Study et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 36-42.
20. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.
21. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class. A hepatitis C virus-induced cirrhosis a 12-year prospective follow-up study. Hepatology 2010; 51: 2069-76.
22. Shiffman ML. Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus. Oncology 2010; 78 (Suppl. 1): 11-6.
23. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41.